Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Takahiro Ochiya currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is being handled by 1 distinct examiner, TURPIN, ZACHARY MARK. The prosecution is localized within 1 distinct art unit, reflecting a focused technical scope for the current active application. Because there is only 1 pending office action, TURPIN, ZACHARY MARK also serves as the busiest examiner with 1 pending matter.
The concentration of the portfolio into 1 distinct art unit and 1 distinct examiner means that the immediate success of the company's patent strategy in Biotechnology & Pharmaceuticals relies on a single point of contact. The presence of 1 pending office action indicates a limited volume of current activity at the patent office. This singular focus allows for a direct prosecution approach with TURPIN, ZACHARY MARK, as there are no other examiners or art units to coordinate with at this time.
With 1 pending office action and 1 distinct examiner, the data shows no fragmentation in the company's current legal efforts. The specific requirements of the 1 distinct art unit will dictate the technical hurdles for the pending matter. As the busiest examiner, TURPIN, ZACHARY MARK holds the entirety of the company's 1 pending office action, making his individual examination style the primary factor in this portfolio's current status.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TURPIN, ZACHARY MARK | 1 | 3.8% | -4.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618412 | METHOD FOR PREDICTING DEVELOPMENT OF SEVERE SYMPTOM OF COVID-19 USING EXOSOMAL PROTEIN MARKER IN BLOOD | TURPIN, ZACHARY MARK | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17618412 | METHOD FOR PREDICTING DEVELOPMENT OF SEVERE SYMPTOM OF COVID-19 USING EXOSOMAL PROTEIN MARKER IN BLOOD | TURPIN, ZACHARY MARK | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTakahiro Ochiya has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Zachary Mark Turpin has the most, with 1 of Takahiro Ochiya's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.